GPR37 is emerging as one of the promising targets for Parkinson’s disease therapy from several lines of evidence: (I) GPR37 was accumulated and upregulated in Lewy bodies of PD patients (Murakami et al., 2004; Wang et al., 2008; Leinartaité and Svenningsson, 2017). Here, GPR37 is linked to Parkinson disease.